Back to today’s briefing

Story perspectives

FDA Approves First New Oral Antibiotic in 30 Years

3/25/2025

46 8

Summary

Story summary

The FDA has made a groundbreaking decision by approving gepotidacin, known as Blujepa, marking the first new oral antibiotic for uncomplicated urinary tract infections in nearly three decades. This innovative treatment targets E. coli, including drug-resistant strains, and has shown superior results compared to nitrofurantoin. Set to launch in late 2025, it promises to tackle a pressing health concern for women.

1 of 1

Story summary

The FDA has made a groundbreaking decision by approving gepotidacin, known as Blujepa, marking the first new oral antibiotic for uncomplicated urinary tract infections in nearly three decades. This innovative treatment targets E. coli, including drug-resistant strains, and has shown superior results compared to nitrofurantoin. Set to launch in late 2025, it promises to tackle a pressing health concern for women.